Short Interest in Aytu BioPharma, Inc. (NASDAQ:AYTU) Decreases By 14.4%

Aytu BioPharma, Inc. (NASDAQ:AYTU) was the recipient of a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 192,800 shares, a decline of 14.4% from the October 15th total of 225,200 shares. Based on an average trading volume of 24,700 shares, the short-interest ratio is presently 7.8 days. Approximately 3.2% of the shares of the company are sold short.

Hedge Funds Weigh In On Aytu BioPharma

Institutional investors have recently modified their holdings of the business. Stonepine Capital Management LLC boosted its stake in Aytu BioPharma by 6.0% during the 3rd quarter. Stonepine Capital Management LLC now owns 500,958 shares of the company’s stock worth $1,177,000 after purchasing an additional 28,489 shares during the period. Armistice Capital LLC acquired a new stake in shares of Aytu BioPharma during the second quarter worth about $736,000. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Aytu BioPharma by 54.5% during the second quarter. Dimensional Fund Advisors LP now owns 23,551 shares of the company’s stock worth $69,000 after buying an additional 8,311 shares during the last quarter. 33.49% of the stock is owned by institutional investors and hedge funds.

Aytu BioPharma Stock Performance

NASDAQ AYTU opened at $1.55 on Monday. The company has a fifty day moving average of $2.21 and a two-hundred day moving average of $2.61. The company has a market capitalization of $9.53 million, a PE ratio of -1.26 and a beta of -1.40. Aytu BioPharma has a 1 year low of $1.49 and a 1 year high of $3.45. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.79.

Aytu BioPharma (NASDAQ:AYTU) last released its quarterly earnings results on Thursday, September 26th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.37). The firm had revenue of $17.98 million for the quarter. Aytu BioPharma had a negative return on equity of 21.89% and a negative net margin of 8.28%.

About Aytu BioPharma

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.